Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Fall;14(3):399-412.

Omega-3s and cardiovascular health

James J DiNicolantonio  1 , Asfandyar K Niazi  2 , Mark F McCarty  3 , James H O'Keefe  4 , Pascal Meier  5 , Carl J Lavie  6
Affiliations
Review

Omega-3s and cardiovascular health

James J DiNicolantonio et al. Ochsner J. 2014 Fall.

Abstract

Background: Omega-3 (n-3) fatty acids have previously been shown to reduce the risk of cardiac events, cardiac death, and all-cause mortality in randomized controlled trials. However, recent data have challenged the benefits of n-3 fatty acids in the current era of optimal medical therapy.

Methods: We performed a literature review indicating important limitations that must be considered when interpreting the recent negative n-3 fatty acids trials.

Results: Our review found relative strengths and weaknesses of both the older and more recent studies, along with many possible explanations for the disparate results. The principal difference between the older and the more recent n-3 studies was a greater use of background optimal medical therapy that may have reduced the benefit from n-3s. Additionally, some of the more recent n-3 trials used relatively low doses or tested n-3 supplementation on top of a relatively high baseline intake of n-3s.

Conclusion: Despite the recent negative data about n-3 fatty acids, the overall evidence still supports the American Heart Association recommendation of 1 gram of eicosapentaenoic acid/docosahexaenoic acid per day for patients with coronary heart disease.

Keywords: Fatty acids–omega-3; fish oils; myocardial infarction.

PubMed Disclaimer

Conflict of interest statement

Financial Disclosure: Dr DiNicolantonio works for a company that sells omega-3 products, but he does not personally profit from the sales. Drs O>'Keefe and Lavie have both served as speakers and consultants to GlaxoSmithKline. Dr Lavie is also a speaker and consultant for Amarin. Mark McCarty is owner and science director of a small nutraceutical company that sells, among other products, a fish oil supplement. Dr O'Keefe is the founder and has major ownership interest in CardioTabs, a company that markets omega-3s. Dr Meier and Asfandyar Niazi disclose no conflicts of interest.

References

    1. Kromhout D, Bosschieter EB. de Lezenne Coulander C. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N Engl J Med. 1985 May 9;312(19):1205–1209. - PubMed
    1. Delgado-Lista J, Perez-Martinez P, Lopez-Miranda J, Perez-Jimenez F. Long chain omega-3 fatty acids and cardiovascular disease: a systematic review. Br J Nutr. 2012 Jun;107((suppl 2)):S201–S213. - PubMed
    1. Stone NJ. Fish consumption, fish oil, lipids, and coronary heart disease. Circulation. 1996 Nov 1;94(9):2337–2340. - PubMed
    1. DiNicolantonio JJ, Niazi AK, O'Keefe JH, Lavie CJ. Explaining the recent fish oil trial “failures.”. J Glycomics Lipidomics. 2013 Dec;3(1): Epub 2012 Nov 15.
    1. Harris WS, Bulchandani D. Why do omega-3 fatty acids lower serum triglycerides? Curr Opin Lipidol. 2006 Aug;17(4):387–393. - PubMed

LinkOut - more resources